Strategic partnerships Rosetta Genomics markets and expands through collaborations in pathology, endocrinology, oncology and urology, indicating sales opportunities through hospital systems, reference labs, and specialty clinics that require integrated molecular testing capabilities.

Product portfolio A diversified test menu including RosettaGX Reveal for thyroid cancer and RosettaGX Cancer Origin, plus core FISH, IHC and PCR testing, offering cross-sell potential to practices adopting multi-modal molecular diagnostics.

Capable labs CAP-accredited, CLIA-certified labs in Philadelphia and Lake Forest demonstrate compliance and reliability, enabling sales outreach to quality-focused buyers who require validated, clinically actionable tests.

Growth history Historical acquisitions and partnerships, such as OncoGxOne and the 2017 merger, suggest openness to collaboration and M&A-driven channels as routes to scale diagnostics offerings in oncology.

Market positioning Operating in a mid-size biotech segment with annual revenue in the tens of millions and a lean employee base, Rosetta Genomics presents opportunities to upsell higher-margin services, lab services, and disease-area expansions to oncology and endocrinology-focused buyers.